|
Cost-effectiveness of dapagliflozin (Forxiga) added to metformin compared with sulfonylurea added to metformin in type 2 diabetes in the Nordic countries |
Sabale U, Ekman M, Granstrom O, Bergenheim K, McEwan P |
|
|
Record Status This is an economic evaluation that meets the criteria for inclusion on NHS EED. Bibliographic details Sabale U, Ekman M, Granstrom O, Bergenheim K, McEwan P. Cost-effectiveness of dapagliflozin (Forxiga) added to metformin compared with sulfonylurea added to metformin in type 2 diabetes in the Nordic countries. Primary Care Diabetes 2014: epub Indexing Status Subject indexing assigned by NLM MeSH Benzhydryl Compounds /adverse effects /economics /therapeutic use; Computer Simulation; Cost-Benefit Analysis; Diabetes Mellitus, Type 2 /blood /diagnosis /drug therapy /economics /epidemiology; Drug Costs; Drug Therapy, Combination; Glucosides /adverse effects /economics /therapeutic use; Humans; Hypoglycemic Agents /adverse effects /economics /therapeutic use; Metformin /adverse effects /economics /therapeutic use; Models, Economic; Quality-Adjusted Life Years; Scandinavian and Nordic Countries /epidemiology; Sulfonylurea Compounds /adverse effects /economics /therapeutic use; Time Factors; Treatment Outcome AccessionNumber 22014022205 Date bibliographic record published 24/06/2014 |
|
|
|